Jeremy Cress, Director of Operations of Fibrocell Science, has 15 years of experience in the biotech/pharmaceutical industry developing and leading solutions-based strategies across all phases of drug development through commercialization, including global manufacturing and distribution. His management experience at Fibrocell is highlighted with the manufacture and commercial scale-up of the first approved cell therapy for aesthetics, LAVIV® azficel-T.
Today, Mr. Cress and his team are working in collaboration with Precigen, Inc., a wholly owned subsidiary of Intrexon Corporation, to advance development of Fibrocell’s gene therapy candidates for the treatment of rare diseases affecting the skin and connective tissue. Currently, the team is focused on FCX-007, the Company’s lead candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)—a devastating, congenital, blistering skin disease with high mortality.
Prior to joining Fibrocell in 2011, Mr. Cress was Director of Operations for Fisher Clinical Services where he had responsibility for manufacturing, domestic and international logistics, and distribution and supply chain activities for >30 pharmaceutical companies and >100 clinical trials.